Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jul 19;367(3):203-13.
doi: 10.1056/NEJMoa1113162.

Radical Prostatectomy Versus Observation for Localized Prostate Cancer

Affiliations
Free PMC article
Randomized Controlled Trial

Radical Prostatectomy Versus Observation for Localized Prostate Cancer

Timothy J Wilt et al. N Engl J Med. .
Free PMC article

Erratum in

  • N Engl J Med. 2012 Aug 9;367(6):582

Abstract

Background: The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known.

Methods: From November 1994 through January 2002, we randomly assigned 731 men with localized prostate cancer (mean age, 67 years; median PSA value, 7.8 ng per milliliter) to radical prostatectomy or observation and followed them through January 2010. The primary outcome was all-cause mortality; the secondary outcome was prostate-cancer mortality.

Results: During the median follow-up of 10.0 years, 171 of 364 men (47.0%) assigned to radical prostatectomy died, as compared with 183 of 367 (49.9%) assigned to observation (hazard ratio, 0.88; 95% confidence interval [CI], 0.71 to 1.08; P=0.22; absolute risk reduction, 2.9 percentage points). Among men assigned to radical prostatectomy, 21 (5.8%) died from prostate cancer or treatment, as compared with 31 men (8.4%) assigned to observation (hazard ratio, 0.63; 95% CI, 0.36 to 1.09; P=0.09; absolute risk reduction, 2.6 percentage points). The effect of treatment on all-cause and prostate-cancer mortality did not differ according to age, race, coexisting conditions, self-reported performance status, or histologic features of the tumor. Radical prostatectomy was associated with reduced all-cause mortality among men with a PSA value greater than 10 ng per milliliter (P=0.04 for interaction) and possibly among those with intermediate-risk or high-risk tumors (P=0.07 for interaction). Adverse events within 30 days after surgery occurred in 21.4% of men, including one death.

Conclusions: Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer mortality, as compared with observation, through at least 12 years of follow-up. Absolute differences were less than 3 percentage points. (Funded by the Department of Veterans Affairs Cooperative Studies Program and others; PIVOT ClinicalTrials.gov number, NCT00007644.).

Conflict of interest statement

No other potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. Study Enrollment and Treatment
Of a total of 13,022 men who were screened for participation, 5023 were eligible for enrollment; of these, 731 were randomly assigned to radical prostatectomy or observation. Of the 364 men in the radical-prostatectomy group, 287 underwent attempted surgery, as did 37 of the 367 men in the observation group. EBRT denotes external-beam radiotherapy.
Figure 2
Figure 2. Kaplan–Meier Plots of Mortality
By the end of the study, 354 men (48.4%) had died from any cause (Panel A). Death attributed to prostate cancer or treatment occurred in 52 men (7.1%) (Panel B). Data from the radical-prostatectomy group are shown in red, and data from the observation group in blue.
Figure 3
Figure 3. Forest Plots for Primary and Secondary Outcomes
There were no significant between-group differences in all-cause mortality according to age, score on the Gleason histologic scale (<7 vs. ≥7 on a scale of 2 to 10, with 10 indicating the most poorly differentiated tumors), self-reported race, self-reported performance status (0 [fully active] vs. 1 to 4, with higher scores indicating poorer functional status), or score on the Charlson co-morbidity index (Panel A), but there was a significant interaction between study group and baseline PSA value (P = 0.04 for interaction) and a borderline interaction (P = 0.07) for tumor risk (D’Amico tumor risk score [low, intermediate, or high], which was based on tumor stage, histologic score, and PSA level). Prostate-cancer mortality did not differ significantly between the study groups according to age, race, score on the Charlson comorbidity index, or self-reported performance status (Panel B), although there was borderline evidence of an interaction for PSA value and tumor-risk category (P = 0.11 for interaction for both comparisons). The bars indicate 95% confidence intervals, and the size of the symbol indicates the weight of the estimate.

Comment in

Similar articles

See all similar articles

Cited by 470 articles

See all "Cited by" articles

Publication types

Substances

Associated data

Feedback